Arrowsmith, John

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery

Computational Drug Discovery MethodsPharmaceutical studies and practices

Cited by 1,450

Phase II and Phase III attrition rates 2011–2012

Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery

Statistical Methods in Clinical TrialsEthics in Clinical Research

Cited by 697

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today

Statistical Methods in Clinical TrialsComputational Drug Discovery Methods

Cited by 692

Phase II failures: 2008–2010

Arrowsmith, J. (2011) · Nature Reviews Drug Discovery

Breast Cancer Treatment StudiesStatistical Methods in Clinical Trials

Cited by 622